De Novo KRAS G12C-Mutant SCLC: A Case Report.

ABSTRACT: The application of KRAS G12C inhibitors in the setting of NSCLC represents a major milestone for a previously "undruggable" target. Here, we present the second reported case of de novo KRAS G12C-mutant primary SCLC. Would our patient benefit from a KRAS G12C inhibitor?

SUBMITTER: Balbach ML 

PROVIDER: S-EPMC9010630 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature